Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY: LLY )

837.29 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 701
Open 837.29
Bid (Size) 837.50 (7)
Ask (Size) 840.50 (4)
Prev. Close 837.29
Today's Range 837.29 - 837.29
52wk Range 434.34 - 846.97
Shares Outstanding N/A
Dividend Yield 0.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
The weight loss drug market is growing rapidly. 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy

Performance

YTD
+41.39%
+41.39%
1 Month
+7.65%
+7.65%
3 Month
+7.32%
+7.32%
6 Month
+42.33%
+42.33%
1 Year
+84.45%
+84.45%

More News

Read More
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
Via Benzinga
Exposures Product Safety
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
Via InvestorPlace
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
Via InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
Via Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
Via Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Via Benzinga
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Via MarketBeat
4 Stocks Making New Highs Despite Market Weakness
Via MarketBeat
The Week Ahead: What's Next
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.